Q-omics provides the consensus-scored LINC01233 profile across patient tissues and cancer cell-line models. LINC01233 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, LINC01233 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, LINC01233 RNA expression shows 11,752 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KICH, and THYM as cancer lineages where LINC01233 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01233 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01233 survival associations across molecular data types. LINC01233 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01233 RNA expression–survival associations across cancer types. High LINC01233 expression shows unfavorable associations in CESC, COAD and READ, but favorable associations in UVM, LGG and ESCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for LINC01233 RNA expression.
This table summarizes LINC01233 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01233. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01233 shows lower tumor expression in KICH, KIRC, BRCA, THCA, LUSC and PAAD. The KICH box plot shows higher LINC01233 RNA expression in normal versus tumor tissue (log2 FC = −0.544, t-test p < 0.001).
This table shows molecular features associated with LINC01233 in patient tissues and cancer cell lines. In patient samples, LINC01233 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
